(Q35544975)

8 August 2017

1 reference

title

Realistic expectations: the management of severe Alzheimer disease (English)

1 reference

8 August 2017

Realistic Expectations: The Management of Severe Alzheimer Disease (English)

1 reference

https://api.crossref.org/works/10.1097/00002093-200307003-00004

15 March 2024

0 references

Roger Bullock

1

1 reference

8 August 2017

Gerry Hammond

2

1 reference

8 August 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

full work available at URL

8 August 2017

http://journals.lww.com/00002093-200307003-00004

1 reference

https://api.crossref.org/works/10.1097/00002093-200307003-00004

Alzheimer Disease and Associated Disorders

15 March 2024

published in

1 reference

8 August 2017

volume

17 Suppl 3

1 reference

8 August 2017

page(s)

S80-5

1 reference

Management of severe Alzheimer's disease and end-of-life issues

8 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/00002093-200307003-00004

Nicotinic acetylcholine involvement in cognitive function in animals

15 March 2024

3

1 reference

https://api.crossref.org/works/10.1097/00002093-200307003-00004

The cholinergic hypothesis of geriatric memory dysfunction

15 March 2024

4

1 reference

https://api.crossref.org/works/10.1097/00002093-200307003-00004

The cholinergic hypothesis of Alzheimer's disease: a review of progress

15 March 2024

5

1 reference

https://api.crossref.org/works/10.1097/00002093-200307003-00004

Treatment of Alzheimer's disease

15 March 2024

6

1 reference

https://api.crossref.org/works/10.1097/00002093-200307003-00004

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

15 March 2024

7

1 reference

https://api.crossref.org/works/10.1097/00002093-200307003-00004

The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease

15 March 2024

8

1 reference

https://api.crossref.org/works/10.1097/00002093-200307003-00004

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

15 March 2024

9

1 reference

https://api.crossref.org/works/10.1097/00002093-200307003-00004

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

15 March 2024

10

1 reference

https://api.crossref.org/works/10.1097/00002093-200307003-00004

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

15 March 2024

11

1 reference

https://api.crossref.org/works/10.1097/00002093-200307003-00004

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

15 March 2024

12

1 reference

https://api.crossref.org/works/10.1097/00002093-200307003-00004

A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.

15 March 2024

13

1 reference

https://api.crossref.org/works/10.1097/00002093-200307003-00004

15 March 2024

“Mini-mental state”

14

1 reference

https://api.crossref.org/works/10.1097/00002093-200307003-00004

A new rating scale for Alzheimer's disease.

15 March 2024

15

1 reference

https://api.crossref.org/works/10.1097/00002093-200307003-00004

Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease

15 March 2024

16

1 reference

https://api.crossref.org/works/10.1097/00002093-200307003-00004

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

15 March 2024

17

1 reference

https://api.crossref.org/works/10.1097/00002093-200307003-00004

Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

15 March 2024

18

1 reference

https://api.crossref.org/works/10.1097/00002093-200307003-00004

Economic considerations in the treatment and management of Alzheimer's disease.

15 March 2024

19

1 reference

https://api.crossref.org/works/10.1097/00002093-200307003-00004

Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease

15 March 2024

20

1 reference

https://api.crossref.org/works/10.1097/00002093-200307003-00004

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study

15 March 2024

21

1 reference

https://api.crossref.org/works/10.1097/00002093-200307003-00004

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

15 March 2024

22

1 reference

https://api.crossref.org/works/10.1097/00002093-200307003-00004

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

15 March 2024

23

1 reference

https://api.crossref.org/works/10.1097/00002093-200307003-00004

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group

15 March 2024

27

1 reference

https://api.crossref.org/works/10.1097/00002093-200307003-00004

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

15 March 2024

28

1 reference

https://api.crossref.org/works/10.1097/00002093-200307003-00004

Rivastigmine for Alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications

15 March 2024

29

1 reference

https://api.crossref.org/works/10.1097/00002093-200307003-00004

Estimated prevalence of Alzheimer's disease in the United States

15 March 2024

30

1 reference

https://api.crossref.org/works/10.1097/00002093-200307003-00004

15 March 2024

Identifiers

1 reference

8 August 2017

1 reference